Slide 1: Q4 and FY26 Results
Q4 and FY26 Results June 3, 2026
Slide 2: Contents
Contents 1 Growth Momentum and Execution 2 Q4 and FY26 Financial Details 3 FY27 Outlook 4 Appendix • Historical Revenue by Geography and Product Category and Key Business Metrics • Historical Financials on a Standalone Basis (Non-GAAP) • GAAP to Non-GAAP Reconciliations for Financials on Standalone
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the developme
Slide 4: Growth Momentum and Execution
Growth Momentum and Execution
Slide 5: Strong finish to FY26 & momentum into FY27
Strong finish to FY26 & momentum into FY27 FY26 record revenue performance surpasses $3B for first time. Q4 revenue and adjusted standalone EBITDA reflects continued growth in the MiniMed 780G system and new sensor launches. International: continued double-digit growth with expanded Simplera product
Slide 6: Q4 FY26 results
Q4 FY26 results Revenue Adjusted standalone EBITDA1 CGM attachment rate2 New pumps sold $837M $154M +8.7% organic 18.4% margin 68% +100 bps Q/Q 42k +7% Q/Q +15.6% reported +500 bps Y/Y -2.5% Y/Y Product revenue mix Geographic revenue mix Pumps United States Other3 $146M l 17% $238M l 28% -HSD% Org Y
Slide 7: Growth acceleration in H2 FY26
Growth acceleration in H2 FY26 Organic revenue growth1 Percent, H1 vs. H2 11.4% Increasing new pumps sold 11.1% 8.6% and CGM attachment rate 7.4% driving H2 growth acceleration 3.1% New pumps sold grew every H1 H2 (0.1%) quarter sequentially WW International US • International: Q3 NPS ~20% H2 vs H1
Slide 8: A complete Gen 3 portfolio upgrade over the next 18 months
A complete Gen 3 portfolio upgrade over the next 18 months Gen 2 Gen 3 AID systems Core Expansion 2023 2026 2025 2026 2027 MiniMed 780G & Flex Simplera & Instinct MiniMed Go MiniMed Fit & Vivera Durable pump AID CGM attachment Smart MDI Patch AID Growth algorithm driven by four engines Q4 and FY26 E
Slide 9: Breaking news: accelerating the pipeline
Breaking news: accelerating the pipeline SmartGuard — MiniMed Go Instinct Sensor MiniMed Flex Abbott Dual Algorithm Advantage US commercial launch International launch Glucose-Ketone New RCT & Real-World Data: with Instinct and with 780G in CE Mark sensor partnership virtually identical outcomes Sim
Slide 10: Q4 and FY26 Financial Details
Q4 and FY26 Financial Details
Slide 11: FY26 results
FY26 results Revenue Adjusted standalone EBITDA1 CGM attachment rate2 New pumps sold $3,102M $482M +8.0% organic 15.6% margin 66% +700 bps Y/Y 145k Unchanged Y/Y +14.2% reported Product revenue mix Geographic revenue mix Pumps United States Other3 $546M l 18% $917M l 30% -LSD% Org Y/Y +LSD% Org Y/Y
Slide 12: Q4 FY26 adjusted standalone EBITDA
Q4 FY26 adjusted standalone EBITDA Adjusted Standalone EBITDA grew 32%... 2x reported revenue growth Margin % impact 16.2% +35 bps +140 bps +240 bps -195 bps 18.4% +$69M -$28M +$4M -$8M $154M $117M Q4 FY25 Adj. Adj. Standalone Adj. Standalone Adj. Standalone Other Items2 Q4 FY26 Adj. Standalone EBIT
Slide 13: FY26 adjusted standalone EBITDA
FY26 adjusted standalone EBITDA Adjusted EBITDA grew 27%... 2x reported revenue growth Margin % impact 14.0% +50 bps +200bps +150 bps -240 bps 15.6% +$241M -$83M -$11M -$45M $482M $381M FY25 Adj. Adj. Standalone Adj. Standalone Adj. Standalone Other Items2 FY26 Adj. Standalone Standalone EBITDA1 Gro
Slide 14: FY27 Outlook
FY27 Outlook
Slide 15: FY27 guidance
FY27 guidance Key assumptions Product launches • MiniMed Flex launch in the US scales through FY27 • MiniMed Go expanding globally • Continued Instinct and Simplera roll-out globally ~10% ~16% Margin expansion • Leverage global sales and marketing infrastructure to continue strong growth FY27 organi
Slide 16: Summary
Summary Upcoming investor meetings Investors.MiniMed.com Strong FY26 finish Strong revenue and adj. standalone EBITDA International double-digit growth US sequential pump momentum on MiniMed 780G adoption and new sensor launches 2026 Scientific Sessions Institutional investor FY27 guidance initiated
Slide 17: Appendix
Appendix 1 Historical Revenue by 4 Additional GAAP to Geography and Non-GAAP Product Category and Reconciliations Key Business Metrics 2 Historical Financials on 5 Acronyms/Glossary a Standalone Basis (Non-GAAP) 3 GAAP to Non-GAAP Reconciliations for Financials on Standalone Basis Q4 and FY26 Earnin
Slide 18: Historical Revenue by Geography and Product Category and Key Business Metrics
Historical Revenue by Geography and Product Category and Key Business Metrics
Slide 19: Historical Revenue by Geography and Product Category and Key Business Metrics
Historical Revenue by Geography and Product Category and Key Business Metrics (in millions) FY25 - Q1 FY25 - Q2 FY25 - Q3 FY25 - Q4 FY25 FY26 - Q1 FY26 - Q2 FY26 - Q3 FY26 - Q4 FY26 Revenue U.S. $211 $227 $231 $234 $903 $212 $224 $242 $238 $917 International $412 $455 $456 $489 $1,812 $511 $527 $548
Slide 20: Historical Financials on a Standalone Basis (Non-GAAP)
Historical Financials on a Standalone Basis (Non-GAAP)
Slide 21: Historical financials on standalone basis (Non-GAAP)
Historical financials on standalone basis (Non-GAAP) Basis of presentation MiniMed’s fiscal year ends on the last Friday of April, following a 52/53-week calendar. The “Income Statement – Standalone Basis” and the “Adjusted Standalone EBITDA” financial measure presented on the following slides are a
Slide 22: Historical financials on standalone basis (Non-GAAP)
Historical financials on standalone basis (Non-GAAP) Income statement on standalone basis (in millions, except where noted) FY25 - Q1 FY25 - Q2 FY25 - Q3 FY25 - Q4 FY25 FY26 - Q1 FY26 - Q2 FY26 - Q3 FY26 - Q4 FY26 Income Statement - Standalone Basis Net Sales (GAAP) $623 $682 $687 $724 $2,715 $723 $
Slide 23: Historical financials on standalone basis (Non-GAAP)
Historical financials on standalone basis (Non-GAAP) Adjusted Standalone EBITDA For a reconciliation of “Adjusted Standalone EBITDA” to Net Income, the most directly comparable GAAP measure, see “GAAP to Non-GAAP Reconciliations” on the following slides. (in millions, except where noted) FY25 - Q1 F
Slide 24: GAAP to Non-GAAP Reconciliations for Financials on Standalone Basis
GAAP to Non- GAAP Reconciliations for Financials on Standalone Basis
Slide 25: GAAP to Non-GAAP reconciliations for financials on standalone basis
GAAP to Non-GAAP reconciliations for financials on standalone basis (in millions, except where noted) FY25 - Q1 FY25 - Q2 FY25 - Q3 FY25 - Q4 FY25 FY26 - Q1 FY26 - Q2 FY26 - Q3 FY26 - Q4 FY26 GAAP to Non-GAAP Reconciliation Net Income ($19) ($5) ($7) ($168) ($198) ($16) ($5) ($111) ($183) ($315) (+)
Slide 26: GAAP to Non-GAAP reconciliations for financials on standalone basis
GAAP to Non-GAAP reconciliations for financials on standalone basis (in millions, except where noted) FY25 - Q1 FY25 - Q2 FY25 - Q3 FY25 - Q4 FY25 FY26 - Q1 FY26 - Q2 FY26 - Q3 FY26 - Q4 FY26 GAAP to Non-GAAP Reconciliation Cost of products sold ($281) ($296) ($292) ($319) ($1,187) ($314) ($323) ($4
Slide 27: GAAP to Non-GAAP reconciliations for financials on standalone basis
GAAP to Non-GAAP reconciliations for financials on standalone basis (in millions, except where noted) FY25 - Q1 FY25 - Q2 FY25 - Q3 FY25 - Q4 FY25 FY26 - Q1 FY26 - Q2 FY26 - Q3 FY26 - Q4 FY26 GAAP to Non-GAAP Reconciliation Other Operating Income/(Expense), net $1 $4 $7 ($4) $8 $2 ($9) ($45) ($168)
Slide 28: GAAP to Non-GAAP reconciliations for financials on standalone basis
GAAP to Non-GAAP reconciliations for financials on standalone basis (in millions, except where noted) FY25 - Q1 FY25 - Q2 FY25 - Q3 FY25 - Q4 FY25 FY26 - Q1 FY26 - Q2 FY26 - Q3 FY26 - Q4 FY26 GAAP to Non-GAAP Reconciliation Operating profit (loss) ($27) $7 $21 ($148) ($146) ($13) $16 ($100) ($91) ($
Slide 29: Additional GAAP to Non-GAAP Reconciliations
Additional GAAP to Non-GAAP Reconciliations
Slide 30: Additional GAAP to Non-GAAP Reconciliations
Additional GAAP to Non-GAAP Reconciliations Q4 and FY26 Earnings 30
Slide 31: Acronyms / Glossary
Acronyms / Glossary
Slide 32: Acronyms and Glossary
Acronyms and Glossary Growth Business Specific MiniMed Product Glossary LSD Low-Single Digit EMR Electronic Medical Record Instinct 15-day sensor made by Abbott MSD Mid-Single Digit FCL Fully Closed Loop MiniMed 780G 2nd gen durable-pump AID HSD High-Single Digit GLP-1 Glucagon-Like Peptide-1 MiniMe